Queen’s University Belfast and Domainex Ltd secure funding from the Wellcome Trust to accelerate early development of first-in-class FLIP inhibitors.
Drug Discovery Pipeline
25th April to 27th April 2016
13th June to 14th June 2016
4th April to 6th April 2016
Domainex will be exhibiting at BioEurope Spring 2016 in Stockholm between April 4-6
Domainex announces the grant of US and European patents for its lead programme, targeting IKK-epsilon and TBK1 for the treatment of COPD and Psoriasis.
2nd November to 4th November 2015
Domainex will attend BioEurope with a view to identifying partners for its discovery phase programmes in inflammatory diseases and
9th March to 11th March 2015
Domainex will attend BioEurope Spring in Paris and be available for discussion on its internal drug discovery pipeline, or drug discovery platform technologies.
12th May to 13th May 2015
Domainex will be in attendance at Biotrinity to discuss its internal drug discovery pipeline focussed on inflammatory and oncology disease indications.
Domainex today announced a potent lead compound in a model of COPD and has also won a £1.4m Biomedical Catalyst Award for Phase I clinical studies
Domainex Ltd. has successfully completed in-vivo studies examining its proprietary selective inhibitors of IKK-epsilon and TBK1 in inflammation models.